Dr. Hoffman-Censits on Biomarker Development in Urothelial Carcinoma

Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses biomarker development in the field of urothelial carcinoma.

There are currently no biomarkers for determining which patients should receive immunotherapy, targeted therapy, or platinum chemotherapy, states Hoffman-Censits.

Biomarkers are being investigated in prospective trials, but all the data is limited to those patients in clinical trials, explains Hoffman-Censits.